◎ Sugi Atlas

Atlas / Drug / Vincristine

Vincristine

drug
On this page

Also known as LeucristineLeurocristineOncotcsTecnocrisVincristinVincristinaVinkristinBisindole derivativeVincristine (VCR)vincristrineSID26757081VincrinstineSID124892473VincristaneSID144205620SID164339426SID170465186

Summary

Vincristine (CHEMBL90555) is an approved small-molecule tubulin modulator (ATC L01CA02) targeting TUBB; indicated across 66 conditions including neoplasm and b-cell chronic lymphocytic leukemia; with CIViC clinical evidence for 3 variant-indication associations (e.g. NF1 Splice Site (c.205-1G>C) AND NF1 G629R in pilocytic astrocytoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01CA02
  • Targets: 1 (TUBB)
  • Indications: 66 conditions
  • Clinical trials: 510
  • Precision-oncology evidence (CIViC): 3 variant–indication associations
  • Chemistry: 825 Da · C46H56N4O10

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL90555
NameVincristine
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID5978
ChEBICHEBI:28445
ATCL01CA02
Molecular formulaC46H56N4O10
Molecular weight825
InChIKeyOGWKCGZFUXNPDA-XQKSVPLYSA-N

SMILES: CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O

IUPAC name: methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate

ChEBI definition: A vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer.

Pharmacological roles (ChEBI): tubulin modulator, microtubule-destabilising agent, antineoplastic agent, drug.

Other ChEBI roles (chemical / environmental): plant metabolite.

Also known as: Leucristine, Leurocristine, Oncotcs, Tecnocris, Vincristin, Vincristina, Vincristine, Vinkristin, vincristine, Bisindole derivative, Vincristine (VCR), vincristrine

Parent form; salt/anhydrous children: CHEMBL501867

Patent coverage: 67,972 distinct patent families (268,031 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 221,660 (83%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
TUBBtubulin beta class IInhibitionP07437

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Prelamin-A/C, Solute carrier organic anion transporter family member 1B1, Solute carrier organic anion transporter family member 1B3, Tubulin, Tubulin, Prostaglandin G/H synthase 1, Multidrug resistance-associated protein 1, Tubulin alpha chain, Huntingtin.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 14 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
LMNA8.96Potency1.1nMCHEMBL_ACT_3624007
HTT7.75Potency17.8nMCHEMBL_ACT_3738423
P025506.66IC50220nMCHEMBL_ACT_173973
TUBB4A6.3IC50500nMCHEMBL_ACT_1212537
Q6B8565.75IC501800nMCHEMBL_ACT_1280514
PTGS15.24AC505726nMCHEMBL_ACT_25206359
SLCO1B35.01Ki9800nMCHEMBL_ACT_12088859

Target pathways

Aggregated over 1 target gene(s): TUBB.

Top Reactome pathways

24 total, by targets touching each:

PathwayTargetsGenes
Cell Cycle1TUBB
Disease1TUBB
Innate Immune System1TUBB
Immune System1TUBB
Organelle biogenesis and maintenance1TUBB
Regulation of PLK1 Activity at G2/M Transition1TUBB
Loss of Nlp from mitotic centrosomes1TUBB
Recruitment of mitotic centrosome proteins and complexes1TUBB
Loss of proteins required for interphase microtubule organization from the centrosome1TUBB
Centrosome maturation1TUBB
Recruitment of NuMA to mitotic centrosomes1TUBB
Mitotic G2-G2/M phases1TUBB
Cilium Assembly1TUBB
Anchoring of the basal body to the plasma membrane1TUBB
Infectious disease1TUBB
Neutrophil degranulation1TUBB
Mitotic Prometaphase1TUBB
M Phase1TUBB
G2/M Transition1TUBB
Cell Cycle, Mitotic1TUBB
AURKA Activation by TPX21TUBB
Potential therapeutics for SARS1TUBB
SARS-CoV Infections1TUBB
Viral Infection Pathways1TUBB

Dominant GO biological processes

GO termTargets
microtubule cytoskeleton organization1
mitotic cell cycle1
microtubule-based process1
cytoskeleton-dependent intracellular transport1
natural killer cell mediated cytotoxicity1
regulation of synapse organization1
spindle assembly1
cell division1
odontoblast differentiation1
cytoskeleton organization1

Indications & clinical

Indications

66 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
neoplasm4MONDO:0005070EFO:0000616
B-cell chronic lymphocytic leukemia3MONDO:0004948EFO:0000095
neoplasm of mature B-cells3MONDO:0004949EFO:0000096
Ewing sarcoma3MONDO:0012817EFO:0000174
HIV infectious disease3MONDO:0005109EFO:0000180
Hodgkins lymphoma3MONDO:0004952EFO:0000183
peripheral T-cell lymphoma, not otherwise specified3MONDO:0004964EFO:0000211
acute lymphoblastic leukemia3MONDO:0004967EFO:0000220
acute myeloid leukemia3MONDO:0018874EFO:0000222
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
leukemia3MONDO:0005059EFO:0000565
lymphoma3MONDO:0005062EFO:0000574
neuroblastoma3MONDO:0005072EFO:0000621
small cell lung carcinoma3MONDO:0008433EFO:0000702
plasma cell myeloma3MONDO:0009693EFO:0001378
medulloblastoma3MONDO:0007959EFO:0002939
brain neoplasm3MONDO:0021211EFO:0003833
lymphoid leukemia3MONDO:0005402EFO:0004289
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
mantle cell lymphoma3MONDO:0018876EFO:1001469
precursor T-cell acute lymphoblastic leukemia3MONDO:0020512EFO:1001830
ganglioneuroblastoma3MONDO:0005035EFO:0000502
central nervous system neoplasm3MONDO:0006130EFO:1000158
hepatoblastoma3MONDO:0018666EFO:1000292
brain cancer3MONDO:0001657MONDO:0001657
ependymoma3MONDO:0016698MONDO:0003478
follicular lymphoma3MONDO:0018906MONDO:0018906
Langerhans cell histiocytosis3MONDO:0018310EFO:1000318
Waldenstrom macroglobulinemia3MONDO:0100280MONDO:0000432
alveolar rhabdomyosarcoma3MONDO:0009994EFO:0000248
embryonal rhabdomyosarcoma3MONDO:0009993EFO:0000437
retinoblastoma3MONDO:0008380MONDO:0008380
glioma3MONDO:0021042MONDO:0021637
B-cell acute lymphoblastic leukemia2MONDO:0004947EFO:0000094
T-cell acute lymphoblastic leukemia2MONDO:0004963EFO:0000209
angioimmunoblastic T-cell lymphoma2MONDO:0004977EFO:0000255
Burkitt lymphoma2MONDO:0007243EFO:0000309
glioblastoma2MONDO:0018177EFO:0000519
anaplastic astrocytoma2MONDO:0016684EFO:0002499
rhabdomyosarcoma2MONDO:0005212EFO:0002918
anaplastic large cell lymphoma2MONDO:0020325EFO:0003032
autoimmune thrombocytopenic purpura2MONDO:0008558EFO:0007160
hemangioma2MONDO:0006500EFO:1000635
blast phase chronic myelogenous leukemia, BCR-ABL1 positive2MONDO:0006115EFO:1000131
T-cell non-Hodgkin lymphoma2MONDO:0015760MONDO:0015760
Wilms tumor2MONDO:0006058MONDO:0019004
hematopoietic and lymphoid system neoplasm2MONDO:0002334MONDO:0044881
adrenal cortex carcinoma2MONDO:0006639EFO:1000796
lymphoid neoplasm2MONDO:0005157EFO:0001642
CD4+/CD56+ hematodermic neoplasm2MONDO:0019467EFO:0010580
acute biphenotypic leukemia2MONDO:0020322MONDO:0019460
osteosarcoma1MONDO:0009807EFO:0000637
sarcoma1MONDO:0005089EFO:0000691
Castleman disease1MONDO:0015564MONDO:0015564
primary effusion lymphoma1MONDO:0018842EFO:1000491
B-cell non-Hodgkin lymphoma1MONDO:0015759EFO:1001938

10 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 510.

Phase distribution

PhaseTrials
PHASE2208
PHASE3118
PHASE161
PHASE1/PHASE257
PHASE429
Not specified25
PHASE2/PHASE36
EARLY_PHASE16

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03892330PHASE4NOT_YET_RECRUITINGCombination Therapy of Anthracyclines for Children With Nephroblastoma
NCT05518383PHASE4RECRUITINGB-cell Mature Non-Hodgkin’s Lymphoma Treatment Protocol in Children and Adolescents 2021
NCT06289673PHASE4RECRUITINGIdentification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
NCT00198978PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00198991PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
NCT00199004PHASE4COMPLETEDTrial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
NCT00199017PHASE4COMPLETEDGerman Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
NCT00199056PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
NCT00199069PHASE4COMPLETEDGerman Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
NCT00199082PHASE4COMPLETEDNewly Diagnosed Mature B-ALL, Burkitt’s Lymphoma and Other High-grade Lymphoma in Adults
NCT00199095PHASE4COMPLETEDTreatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia
NCT00411541PHASE4COMPLETEDPulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia
NCT00491946PHASE4UNKNOWNA Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer
NCT00494897PHASE4COMPLETEDPETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
NCT00526175PHASE4COMPLETEDLAL-BR/2001: Study Treatment to Low Risk ALL
NCT00526305PHASE4COMPLETEDLAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
NCT00526409PHASE4COMPLETEDLAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia
NCT00846703PHASE4UNKNOWNThe GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia
NCT00853008PHASE4COMPLETEDTreatment of High Risk Adult Acute Lymphoblastic Leukemia
NCT01358201PHASE4UNKNOWNPETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph’ Negative Over 55 Years
NCT01358253PHASE4COMPLETEDRituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
NCT01746992PHASE4UNKNOWNCTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
NCT02036489PHASE4COMPLETEDPethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
NCT02752815PHASE4UNKNOWNReduced Chemotherapy in Low Risk DLBCL
NCT02858804PHASE4COMPLETEDEDOCH Alternating With DHAP for New Diagnosed Younger MCL
NCT02894645PHASE4UNKNOWNMalaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
NCT03229746PHASE4COMPLETEDReposition of Second Line Treatment in Chronic Immune Thrombocytopenia
NCT03817853PHASE4COMPLETEDAn Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
NCT05844670PHASE4UNKNOWNCHildren Treated With Vincristine: A Trial Regarding Pharmacokinetics, DNA And Toxicity of Targeted Therapy In Pediatric Oncology Patients.
NCT00887146PHASE3ACTIVE_NOT_RECRUITINGRadiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
NCT01704716PHASE3RECRUITINGHigh Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
NCT02003222PHASE3ACTIVE_NOT_RECRUITINGCombination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
NCT02101853PHASE3ACTIVE_NOT_RECRUITINGBlinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02112916PHASE3ACTIVE_NOT_RECRUITINGCombination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
NCT02306161PHASE3ACTIVE_NOT_RECRUITINGCombination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
NCT02405676PHASE2/PHASE3ACTIVE_NOT_RECRUITINGBNHL-2015 for Children or Adolescents in China
NCT02455245PHASE3ACTIVE_NOT_RECRUITINGA Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma
NCT02661503PHASE3ACTIVE_NOT_RECRUITINGHD21 for Advanced Stages
NCT02845882PHASE3ACTIVE_NOT_RECRUITINGLBL-2016 for Children or Adolescents in China
NCT03017326PHASE3ACTIVE_NOT_RECRUITINGPaediatric Hepatic International Tumour Trial

Clinical evidence (CIViC)

Variant × indication × effect (3 predictive associations from 3 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
NF1 Splice Site (c.205-1G>C) AND NF1 G629RPilocytic AstrocytomaSensitivity/ResponseVincristine + Carboplatin + Trametinib + SelumetinibCIViC CEID12271
NUP214::ABL1 FusionB-lymphoblastic Leukemia/lymphoma, BCR-ABL1–likeSensitivity/ResponseVincristine + Dexamethasone + DasatinibCIViC CEID7208
ZEB1 ExpressionMantle Cell LymphomaResistanceVincristineCIViC DEID12502

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 23 clinical and 179 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

17 molecules share ≥1 primary target. Top 17 by shared-target count:

MoleculeSourceStatusShared targets
PODOFILOXChEMBL + PubChemPhase 4 (approved)TUBB
VINBLASTINEChEMBL + PubChemPhase 4 (approved)TUBB
COLCHICINEChEMBLPhase 4 (approved)TUBB
DOCETAXELChEMBLPhase 4 (approved)TUBB
LEVOFLOXACINChEMBLPhase 4 (approved)TUBB
NOSCAPINEChEMBLPhase 4 (approved)TUBB
PACLITAXELChEMBLPhase 4 (approved)TUBB
TIRBANIBULINChEMBLPhase 4 (approved)TUBB
VINORELBINEChEMBLPhase 4 (approved)TUBB
PATUPILONEChEMBLPhase 3TUBB
ABT-751ChEMBLPhase 2TUBB
DOLASTATIN-10ChEMBLPhase 2TUBB
INDIBULINChEMBLPhase 2TUBB
MAYTANSINEChEMBLPhase 2TUBB
MOLIBRESIBChEMBLPhase 2TUBB
NOCODAZOLEChEMBLPhase 2TUBB
PARBENDAZOLEChEMBLPhase 2TUBB

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot